Joanne H. Reed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joanne H. Reed has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Christopher C. Goodnow
Garvan Institute of Medical Research, Sydney, Australia
12 shared publications - Jill P. Buyon
Division of Rheumatology, New York University School of Medicine
10 shared publications - Adrian Yong Sing Lee
Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
9 shared publications - Tom Paul Gordon
Department of Immunology, Flinders University and SA Pathology, Bedford Park, Adelaide, SA, Australia
9 shared publications Robert M. Clancy
Dept. Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA
7 shared publicationsTom P. Gordon
SA Pathology and Flinders University Bedford Park South Australia Australia
7 shared publications
Latest Publications
- Open Access
B cell tolerance is dysregulated in people with complex regional pain syndrome: A high-dimensional immunophenotyping study
Complex regional pain syndrome (CRPS) is a devastating chronic pain disorder that typically arises after distal limb trauma. It has a complex, multi-system pathophysiology that is not well understood, preventing the development of targeted therapies. Observations of self-reactive antibodies in CRPS patients that can elicit pain hypersensitivity in rodents have established an autoimmune contribution to the onset and maintenance of CRPS-like pain, although the mechanisms underlying this remain unclear. To understand the development of pathogenic autoantibody responses in CRPS, this study performed the first high-dimensional characterisation of B cell activity in a cohort of 42 CRPS patients and 42 matched healthy controls. Immunophenotyping of peripheral immune cell populations by mass cytometry identified altered frequencies of class-switched and double-negative memory B cell subsets in CRPS, and increased use of autoimmune-associated IGHV1-69 and IGHV4-34 gene-encoded heavy-chains within the class-switched B cell compartment. Additional proteomic and autoantibody assessments identified differences in serum protein and IgA autoantibody profiles that may lead to altered complement signalling and pro-inflammatory cytokine production in CRPS. Together, these findings represent evidence of dysregulated B cell self-tolerance in CRPS that could facilitate production of pathogenic autoantibodies in people with the condition.
Open AccessB cell tolerance is dysregulated in people with complex regional pain syndrome: A high-dimensional immunophenotyping study
Complex regional pain syndrome (CRPS) is a devastating chronic pain disorder that typically arises after distal limb trauma. It has a complex, multi-system pathophysiology that is not well understood, preventing the development of targeted therapies. Observations of self-reactive antibodies in CRPS patients that can elicit pain hypersensitivity in rodents have established an autoimmune contribution to the onset and maintenance of CRPS-like pain, although the mechanisms underlying this remain unclear. To understand the development of pathogenic autoantibody responses in CRPS, this study performed the first high-dimensional characterisation of B cell activity in a cohort of 42 CRPS patients and 42 matched healthy controls. Immunophenotyping of peripheral immune cell populations by mass cytometry identified altered frequencies of class-switched and double-negative memory B cell subsets in CRPS, and increased use of autoimmune-associated IGHV1-69 and IGHV4-34 gene-encoded heavy-chains within the class-switched B cell compartment. Additional proteomic and autoantibody assessments identified differences in serum protein and IgA autoantibody profiles that may lead to altered complement signalling and pro-inflammatory cytokine production in CRPS. Together, these findings represent evidence of dysregulated B cell self-tolerance in CRPS that could facilitate production of pathogenic autoantibodies in people with the condition.
- Open Access
Apoptotic bodies from patients with Sjögren’s disease drive atypical memory B cell and macrophage activation and autoantibody production
The impaired clearance of apoptotic cells has long been associated with systemic autoimmune diseases like Sjögren’s disease (SjD), which is characterised by autoantibodies targeting antigens on apoptotic cells. However, most studies analysing human samples have used patient-derived phagocytes and in vitro generated apoptotic cells, which do not reflect the heterogeneity of patient-derived apoptotic bodies (ApoBDs). Here, we molecularly and functionally compare ApoBDs derived from patients with SjD and healthy donors. ApoBDs were increased in the circulation in SjD and induced atypical memory B cell expansion, which was attenuated by blocking B cell receptor (BCR) and Toll-like receptors (TLR) 7-9 signalling. Co-cultures of ApoBDs and B cells drove autoantibody production. Macrophages engulfing SjD ApoBDs had a distinct inflammatory profile compared to macrophages engulfing healthy control ApoBDs. These findings define patient-derived ApoBDs as immunostimulatory substrates capable of driving innate and adaptive immune responses consistent with the pathogenic features observed in SjD, hence opening a new avenue of diagnostic and therapeutic development.
Open AccessApoptotic bodies from patients with Sjögren’s disease drive atypical memory B cell and macrophage activation and autoantibody production
The impaired clearance of apoptotic cells has long been associated with systemic autoimmune diseases like Sjögren’s disease (SjD), which is characterised by autoantibodies targeting antigens on apoptotic cells. However, most studies analysing human samples have used patient-derived phagocytes and in vitro generated apoptotic cells, which do not reflect the heterogeneity of patient-derived apoptotic bodies (ApoBDs). Here, we molecularly and functionally compare ApoBDs derived from patients with SjD and healthy donors. ApoBDs were increased in the circulation in SjD and induced atypical memory B cell expansion, which was attenuated by blocking B cell receptor (BCR) and Toll-like receptors (TLR) 7-9 signalling. Co-cultures of ApoBDs and B cells drove autoantibody production. Macrophages engulfing SjD ApoBDs had a distinct inflammatory profile compared to macrophages engulfing healthy control ApoBDs. These findings define patient-derived ApoBDs as immunostimulatory substrates capable of driving innate and adaptive immune responses consistent with the pathogenic features observed in SjD, hence opening a new avenue of diagnostic and therapeutic development.
- 3 May 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (6) , 582-585
Highlights of 2025: the B‐side of LEF1
In this article of the Highlights of 2025 series, we review the latest discovery of LEF1 function in B cell biology. These discoveries provide novel insights into the LEF1 function on B cell maintenance in cancer and autoimmunity, uncovering new opportunities for the development of a more specific B cell targeting approach.
- 3 May 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (6) , 582-585
Highlights of 2025: the B‐side of LEF1
In this article of the Highlights of 2025 series, we review the latest discovery of LEF1 function in B cell biology. These discoveries provide novel insights into the LEF1 function on B cell maintenance in cancer and autoimmunity, uncovering new opportunities for the development of a more specific B cell targeting approach.
- 1 May 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (6) , 578-581
Origins and drivers of self‐reactive B cells in autoimmune disease
Self‐reactive B cells are a hallmark of autoimmune disease and may directly contribute to disease pathogenesis. This Research Highlight article reviews four articles published in 2025 that offer new insights into the origins and drivers of self‐reactive B cells. These studies investigate self‐reactive B cells in human peripheral blood, murine models, and the role of viral and genetic drivers.
- 1 May 2026
- Published by Wiley in Immunology & Cell Biology
- Vol. 104 (6) , 578-581
Origins and drivers of self‐reactive B cells in autoimmune disease
Self‐reactive B cells are a hallmark of autoimmune disease and may directly contribute to disease pathogenesis. This Research Highlight article reviews four articles published in 2025 that offer new insights into the origins and drivers of self‐reactive B cells. These studies investigate self‐reactive B cells in human peripheral blood, murine models, and the role of viral and genetic drivers.
- Open Access
- 7 April 2026
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 12, 100370
Longitudinal evolution of rheumatoid factor-expressing lymphoma precursors in a patient with Sjögren's disease
- 7 April 2026
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 12, 100370
Open AccessLongitudinal evolution of rheumatoid factor-expressing lymphoma precursors in a patient with Sjögren's disease
- Open Access
- 18 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody
Preventing autoantibody secretion by rendering self-reactive B cells functionally silent through clonal anergy has long posed the question of why fill the circulating B cell repertoire with cells that cannot secrete antibody? Here we address this question from the perspective of B cells that comprise 5 to 10% of the human circulating repertoire, expressing self-reactive surface immunoglobulins employing the IGHV4-34 heavy chain variable element. Using gene targeting to construct mice expressing a representative human IGHV4-34 antibody on the surface of many B cells, we show these cells are prevented from autoantibody secretion by B cell clonal anergy marked by downregulation of surface IgM, induction of tolerance-response mRNAs, and exclusion from the marginal zone and B1 cell subsets. This functionally tolerant state is overridden when the IGHV4-34 B cells cross-react with a virus, which stimulates the self-reactive B cells to hypermutate in germinal centers. Within 16 d of infection, 99% of daughter cells have acquired one of five heavy chain mutations that diminish binding to self but preserve virus binding, and 33% had combined 2 or 3 of these mutations to make their antibodies genetically self-tolerant and virus specific. These results demonstrate, from the perspective of a pathologically important human autoantibody class and the world’s most successful virus vaccine, how human antibody specificity is sculpted in the progeny of anergic B cells to yield antibodies that bind a virus but not self.
- 18 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (51)
Open AccessConvergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody
Preventing autoantibody secretion by rendering self-reactive B cells functionally silent through clonal anergy has long posed the question of why fill the circulating B cell repertoire with cells that cannot secrete antibody? Here we address this question from the perspective of B cells that comprise 5 to 10% of the human circulating repertoire, expressing self-reactive surface immunoglobulins employing the IGHV4-34 heavy chain variable element. Using gene targeting to construct mice expressing a representative human IGHV4-34 antibody on the surface of many B cells, we show these cells are prevented from autoantibody secretion by B cell clonal anergy marked by downregulation of surface IgM, induction of tolerance-response mRNAs, and exclusion from the marginal zone and B1 cell subsets. This functionally tolerant state is overridden when the IGHV4-34 B cells cross-react with a virus, which stimulates the self-reactive B cells to hypermutate in germinal centers. Within 16 d of infection, 99% of daughter cells have acquired one of five heavy chain mutations that diminish binding to self but preserve virus binding, and 33% had combined 2 or 3 of these mutations to make their antibodies genetically self-tolerant and virus specific. These results demonstrate, from the perspective of a pathologically important human autoantibody class and the world’s most successful virus vaccine, how human antibody specificity is sculpted in the progeny of anergic B cells to yield antibodies that bind a virus but not self.
- 18 June 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (6) , 490-491
ICB Special Feature: Highlights of 2024
- 18 June 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (6) , 490-491
ICB Special Feature: Highlights of 2024
- 27 April 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (6) , 500-503
Highlights of 2024: The rising role of age‐associated B cells in autoimmune diseases
In this Research Highlight, we explore 5 influential basic and translational articles published in 2024 that shed light on the biology of age-associated B cells (ABCs) and their emerging role in autoimmunity.
- 27 April 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (6) , 500-503
Highlights of 2024: The rising role of age‐associated B cells in autoimmune diseases
In this Research Highlight, we explore 5 influential basic and translational articles published in 2024 that shed light on the biology of age-associated B cells (ABCs) and their emerging role in autoimmunity.
- Open Access
- 17 February 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (4) , 401-410
Self‐reactive B cells are increased in all major stages of peripheral development in Sjögren's disease
Sjögren's disease (SjD) is a chronic autoimmune disorder characterized by increased circulating self‐reactive B cells. While many of these self‐reactive B cells emerge from the bone marrow, it is not known whether they are excluded from or enriched in specific developmental stages in the periphery. The aim of this study was to determine the immunophenotype of circulating self‐reactive B cells in SjD to inform more precise therapeutic targeting. Five major B cell populations: transitional, mature naïve, switched memory, double negative and plasmablasts were single‐cell sorted and cultured to produce IgG. Self‐reactive IgG was identified by ELISA, flow cytometry of permeabilized HEK293 cells and HEp‐2 indirect immunofluorescence. Immunoglobulin heavy chains were sequenced by Sanger and next‐generation sequencing. Compared with healthy donor controls (HCs), SjD patients had higher frequencies of naïve and CD21low atypical memory B cell subsets, while antigen‐experienced B cells expressed more Ki67 and CD86. B cells recognizing intracellular self‐antigens were identified in all stages of peripheral B cell development for SjD and HCs, but frequencies of autoreactive B cells were up to 10‐fold higher in SjD. Self‐reactive transitional B cells expressed higher surface CD38 and lower surface IgM. An increase in self‐reactive B cells throughout peripheral development in SjD compared with HCs suggests that counterselection of autoantibody‐bearing B cells during central and peripheral tolerance checkpoints are reduced in SjD. Therapeutic strategies focused on depleting B cells based on B cell receptor specificity rather than the developmental stage would be more efficient to target self‐reactive B cells in SjD.
- 17 February 2025
- Published by Wiley in Immunology & Cell Biology
- Vol. 103 (4) , 401-410
Open AccessSelf‐reactive B cells are increased in all major stages of peripheral development in Sjögren's disease
Sjögren's disease (SjD) is a chronic autoimmune disorder characterized by increased circulating self‐reactive B cells. While many of these self‐reactive B cells emerge from the bone marrow, it is not known whether they are excluded from or enriched in specific developmental stages in the periphery. The aim of this study was to determine the immunophenotype of circulating self‐reactive B cells in SjD to inform more precise therapeutic targeting. Five major B cell populations: transitional, mature naïve, switched memory, double negative and plasmablasts were single‐cell sorted and cultured to produce IgG. Self‐reactive IgG was identified by ELISA, flow cytometry of permeabilized HEK293 cells and HEp‐2 indirect immunofluorescence. Immunoglobulin heavy chains were sequenced by Sanger and next‐generation sequencing. Compared with healthy donor controls (HCs), SjD patients had higher frequencies of naïve and CD21low atypical memory B cell subsets, while antigen‐experienced B cells expressed more Ki67 and CD86. B cells recognizing intracellular self‐antigens were identified in all stages of peripheral B cell development for SjD and HCs, but frequencies of autoreactive B cells were up to 10‐fold higher in SjD. Self‐reactive transitional B cells expressed higher surface CD38 and lower surface IgM. An increase in self‐reactive B cells throughout peripheral development in SjD compared with HCs suggests that counterselection of autoantibody‐bearing B cells during central and peripheral tolerance checkpoints are reduced in SjD. Therapeutic strategies focused on depleting B cells based on B cell receptor specificity rather than the developmental stage would be more efficient to target self‐reactive B cells in SjD.